Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

Inclusion Criteria: * Histological or pathological diagnosis of head and neck squamous cell carcinoma; * Initially resectable stage III-IVB oral cancer/laryngeal cancer/hypopharyngeal cancer/P16-oropharyngeal cancer, or stage III p16+ oropharyngeal cancer (AJCC 8th), and evaluated by the researcher to achieve R0 resection; * Plan to perform neoadjuvant therapy; * No previous anti-tumor treatment for HNSCC; * There is at least one measurable lesion; * Eastern Cooperative Oncology Group Performance Status (ECOG) score 0-2; * The expected survival period is ≥3 months * The functions of vital organs meet the following requirements (excluding any blood components and cell growth factors used within 7 days) : i. Normal bone marrow reserve function, white blood cell (WBC) ≥3.0×109/L; Neutrophil count (NEUT) ≥ 1.5×109/L, platelet count (PLT) ≥100×109/L, hemoglobin (Hb) ≥90 g/L; ii. Normal renal function or serum creatinine (SCr) ≤ 1.5 times the upper limit of normal value (ULN) or creatinine clearance rate ≥50 ml/min (Cockcroft-Gault formula); iii. Normal liver function or total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN); The level of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is ≤ 2.5 times the upper limit of the normal value (ULN). * Be able to and willing to abide by the research and follow-up procedures; * Men and women of gestational age must agree to take adequate contraceptive measures throughout the study period and within 6…